123 related articles for article (PubMed ID: 7748464)
21. L-DOPA does not facilitate nitric oxide production in the rat striatum and substantia nigra: in vivo microdialysis study.
Kashihara K; Sakai K; Marui K; Shohmori T
Life Sci; 1998; 63(4):PL59-64. PubMed ID: 9698040
[TBL] [Abstract][Full Text] [Related]
22. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
Lindefors N; Brodin E; Tossman U; Segovia J; Ungerstedt U
Exp Brain Res; 1989; 74(3):527-34. PubMed ID: 2468514
[TBL] [Abstract][Full Text] [Related]
23. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
Brannan T; Knott P; Kaufmann H; Yahr M
Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
[No Abstract] [Full Text] [Related]
24. Effects of intranigral substance P and neurokinin A on striatal dopamine release--II. Interactions with bicuculline and naloxone.
Reid MS; Herrera-Marschitz M; Ungerstedt U
Neuroscience; 1990; 36(3):659-67. PubMed ID: 1700330
[TBL] [Abstract][Full Text] [Related]
25. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.
Lapchak PA; Beck KD; Araujo DM; Irwin I; Langston JW; Hefti F
Neuroscience; 1993 Apr; 53(3):639-50. PubMed ID: 8098137
[TBL] [Abstract][Full Text] [Related]
26. L-DOPA modulation of corpus striatal dopamine and dihydroxyphenylacetic acid output from intact and 6-OHDA lesioned rats.
Xu K; Dluzen DE
J Neural Transm (Vienna); 1996; 103(11):1295-305. PubMed ID: 9013416
[TBL] [Abstract][Full Text] [Related]
27. Biotransformation of L-DOPA to dopamine in the substantia nigra of freely moving rats: effect of dopamine receptor agonists and antagonists.
Sarre S; Vandeneede D; Ebinger G; Michotte Y
J Neurochem; 1998 Apr; 70(4):1730-9. PubMed ID: 9523592
[TBL] [Abstract][Full Text] [Related]
28. Acute effects of intranigral application of MPP+ on nigral and bilateral striatal release of dopamine simultaneously recorded by microdialysis.
Santiago M; Rollema H; de Vries JB; Westerink BH
Brain Res; 1991 Jan; 538(2):226-30. PubMed ID: 1707325
[TBL] [Abstract][Full Text] [Related]
29. Taurine infused intrastriatally elevates, but intranigrally decreases striatal extracellular dopamine concentration in anaesthetised rats.
Ruotsalainen M; Heikkilä M; Lillsunde P; Seppälä T; Ahtee L
J Neural Transm (Vienna); 1996; 103(8-9):935-46. PubMed ID: 9013387
[TBL] [Abstract][Full Text] [Related]
30. In vivo release of dopamine from rat striatum, substantia nigra and prefrontal cortex: differential modulation by baclofen.
Santiago M; Machado A; Cano J
Br J Pharmacol; 1993 Jul; 109(3):814-8. PubMed ID: 7689406
[TBL] [Abstract][Full Text] [Related]
31. Comparison of changes in locomotor activity with striatal homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations following the bilateral intranigral injection of dopamine agonist drugs in rats.
Kelly E; Jenner P; Marsden CD
J Pharm Pharmacol; 1987 Mar; 39(3):196-202. PubMed ID: 2883284
[TBL] [Abstract][Full Text] [Related]
32. Increased dopamine metabolism in rat striatum after infusions of substance P into the substantia nigra.
Waldmeier PC; Kam R; Stöcklin K
Brain Res; 1978 Dec; 159(1):223-7. PubMed ID: 728796
[No Abstract] [Full Text] [Related]
33. Intranigral GABAergic drug effects on striatal dopamine activity.
Sperber EF; Wurpel JN; Sharpless NS; Moshé SL
Pharmacol Biochem Behav; 1989 Apr; 32(4):1067-70. PubMed ID: 2477863
[TBL] [Abstract][Full Text] [Related]
34. Iron(III) chloride injection increases nigral uric acid in guinea-pig.
Ward VL; McGinty JF; Church WH
Neuroreport; 1993 Jun; 4(6):787-90. PubMed ID: 8347827
[TBL] [Abstract][Full Text] [Related]
35. Effects of midazolam and flunitrazepam on the release of dopamine from rat striatum measured by in vivo microdialysis.
Takada K; Murai T; Kanayama T; Koshikawa N
Br J Anaesth; 1993 Feb; 70(2):181-5. PubMed ID: 8435263
[TBL] [Abstract][Full Text] [Related]
36. Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats.
Lorenc-Koci E; Lenda T; Antkiewicz-Michaluk L; Wardas J; Domin H; Smiałowska M; Konieczny J
Neurochem Int; 2011 Jun; 58(7):839-49. PubMed ID: 21419185
[TBL] [Abstract][Full Text] [Related]
37. Intranigral substance P modulation of striatal dopamine: interaction with N-terminal and C-terminal substance P fragments.
Reid MS; Herrera-Marschitz M; Terenius L; Ungerstedt U
Brain Res; 1990 Sep; 526(2):228-34. PubMed ID: 1701682
[TBL] [Abstract][Full Text] [Related]
38. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine.
Santiago M; Granero L; Machado A; Cano J
Eur J Pharmacol; 1995 Jul; 280(3):251-6. PubMed ID: 8566093
[TBL] [Abstract][Full Text] [Related]
39. Effects of baclofen on striatal 5-HT mediated by the nigrostriatal dopamine system.
Waldmeier PC; Feldtrauer JJ; Kam R; Stöcklin K
Eur J Pharmacol; 1979 Mar; 54(3):279-87. PubMed ID: 428427
[TBL] [Abstract][Full Text] [Related]
40. Biotransformation of locally applied L-dopa in the corpus striatum of the hemi-parkinsonian rat studied with microdialysis.
Sarre S; De Klippel N; Herregodts P; Ebinger G; Michotte Y
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jul; 350(1):15-21. PubMed ID: 7935849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
